Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.51 |
| ▸ | ITGB2 | P05107 | 3/20 | 0.47 |
| ▸ | ICAM1 | P05362 | 3/20 | 0.47 |
| ▸ | ITGAL | P20701 | 3/20 | 0.47 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.45 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25669860 | 0.91 | SLC6A5 (0.54) | SLC6A5CYP3A4CYP2D6TSHRCYP2C19 | |
| SCHEMBL16364168 | 0.87 | CYP3A4 (0.54) | SLC6A5CYP3A4CYP2D6TSHRCYP2C19 | |
| Carnosine SCHEMBL1160796 | 0.86 | SLC15A2 (0.63) | SLC6A5CYP3A4CYP2D6TSHRCYP2C19 | |
| Carnosine SCHEMBL1161102 | 0.86 | SLC15A2 (0.63) | SLC6A5CYP3A4CYP2D6TSHRCYP2C19 | |
| Carnosine SCHEMBL22392772 | 0.86 | SLC15A2 (0.63) | SLC6A5CYP3A4CYP2D6TSHRCYP2C19 | |
| SCHEMBL18381283 | 0.85 | SLC6A5 (0.51) | SLC6A5CYP3A4CYP2D6TSHRCYP2C19 | |
| SCHEMBL18381307 | 0.85 | CYP3A4 (0.52) | SLC6A5CYP3A4CYP2D6TSHRCYP2C19 | |
| SCHEMBL21089953 | 0.85 | CYP3A4 (0.52) | SLC6A5CYP3A4CYP2D6TSHRCYP2C19 | |
| SCHEMBL16551861 | 0.85 | CYP3A4 (0.52) | SLC6A5CYP3A4CYP2D6TSHRCYP2C19 | |
| Carnosine SCHEMBL30129832 | 0.85 | SLC15A2 (0.61) | SLC6A5CYP3A4CYP2D6TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220162171-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL POLYPS | Cellix Bio Provate Limited (IN) | 2022-05-26 | — | — | US | disclosed |
| US-20220048850-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | CELLIX BIO PRIVATE LTD (IN) | 2022-02-17 | — | — | US | disclosed |
| US-11225464-B2 | Compositions and methods for the treatment of gastrointestinal polyps | CELLIX BIO PRIVATE LIMITED (IN) | 2022-01-18 | — | — | US | disclosed |
| US-20210277050-A1 | OPHTHALMIC COMPOSITIONS AND METHODS FOR THE TREATMENT OF EYE DISORDERS | CELLIX BIO PRIVATE LIMITED (IN) | 2021-09-09 | — | — | US | disclosed |
| US-11078154-B2 | Compositions and methods for the treatment of irritable bowel syndrome | CELLIX BIO PRIVATE LIMITED (IN) | 2021-08-03 | — | — | US | disclosed |
| US-20200190040-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL POLYPS | CELLIX BIO PRIVATE LIMITED (IN) | 2020-06-18 | — | — | US | disclosed |
| US-20190177267-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | CELLIX BIO PRIVATE LIMITED (IN) | 2019-06-13 | — | — | US | disclosed |
| US-8093427-B2 | Construction and screening of solution-phase derived library of fenbufen and ethacrynic acid | NATIONAL TSING HUA UNIVERSITY (TW) | 2012-01-10 | — | — | US | disclosed |
| US-20110306668-A1 | CONSTRUCTION AND SCREENING OF SOLUTION-PHASE DERIVED LIBRARY OF FENBUFEN AND ETHACRYNIC ACID | NATIONAL TSING HUA UNIVERSITY (TW) | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11225464-B2 | Compositions and methods for the treatment of gastrointestinal polyps | APC, LPXN, SCNN1G | SLC6A5 282/4885CYP3A4 82/4885CYP2D6 144/4885 |
| US-20220048850-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | IL1B, IL36G, IL17A | SLC6A5 819/4885CYP3A4 50/4885CYP2D6 75/4885 |
| US-11078154-B2 | Compositions and methods for the treatment of irritable bowel syndrome | SI, SLC10A2, ALPI | SLC6A5 100/4885CYP3A4 94/4885CYP2D6 19/4885 |
| US-20190177267-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | SI, SLC10A2, F5 | SLC6A5 360/4885CYP3A4 20/4885CYP2D6 6/4885 |
| US-20200190040-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL POLYPS | APC, LPXN, SCNN1G | SLC6A5 282/4885CYP3A4 82/4885CYP2D6 144/4885 |
| US-20220162171-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL POLYPS | APC, LPXN, SCNN1G | SLC6A5 282/4885CYP3A4 82/4885CYP2D6 144/4885 |
| US-20210277050-A1 | OPHTHALMIC COMPOSITIONS AND METHODS FOR THE TREATMENT OF EYE DISORDERS | F5, OR10J3, SHBG | SLC6A5 290/4885CYP3A4 25/4885CYP2D6 34/4885 |
| US-20110306668-A1 | CONSTRUCTION AND SCREENING OF SOLUTION-PHASE DERIVED LIBRARY OF FENBUFEN AND ETHACRYNIC ACID | CYP4F2, ACR, CYP4F3 | SLC6A5 3159/4885CYP3A4 179/4885CYP2D6 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.